|
PubHealth.info®
(a subsidiary of
PakMed) presents scientific information mainly
based on abstracts of articles published on a variety of public health issues/topics,
particularly encompassing
population planning, disease prevention, maternal and child health,
and communicable and
non-communicable diseases (like HIV AIDS, malaria, etc) that are
affecting a significant portion of population in developing and
developed
countries. Here you can find abstracts of articles published on a variety of public health
topics under category "Contraception
(Birth Control) and Family Planning".
Contraception (birth control)
is a regimen of one or more actions, devices, or medications followed in
order to deliberately prevent or reduce the likelihood of a woman
becoming pregnant or giving birth. Therefore contraception is the
utilization of various and sundry surgical procedures, devices,
practices, agents, or drugs with the intention of preventing conception
or impregnation (pregnancy). Methods and intentions typically termed
birth control may be considered a pivotal ingredient to family
planning. Birth control is a controversial political and ethical
issue in many cultures and religions, and although it is generally less
controversial than abortion specifically. |
|
|
| CATEGORY: |
Contraception (Birth Control) and Family Planning |
| Anastrazole and oral contraceptives: a novel treatment for endometriosis. |
| Amsterdam LL; Gentry W; Jobanputra S; Wolf M; Rubin SD |
| Fertility and Sterility. 2005 Aug;84(2):300-304. |
| Objective: To establish the use of aromatase inhibitors as a therapeutic option for endometriosis. Design: |
| Prospective open-label Food and Drug Administration phase 2 trial with Institutional Review Board approval. Setting: |
| Outpatient tertiary care centers. Patient(s): Fifteen premenopausal patients with documented refractory endometriosis |
| and chronic pelvic pain. Intervention(s): After a 1-month washout of endometriosis hormone therapies, women took 1 |
| mg anastrazole (Arimidex; AstraZeneca, Wilmington, DE) and one tablet of 20 µg ethinyl estradiol/0.1 mg |
| levonorgestrel (Alesse; Wyeth, Madison, NJ) daily for 6 months. Main Outcome Measure(s): An analog pain scale |
| recorded pelvic pain in daily diaries and surveys at baseline and after each treatment month. Side effects, blood |
| counts, liver and renal function tests, cholesterol levels, and bone density were monitored. Result(s): Fourteen of 15 |
| patients achieved significant pain reduction. Median pain scores decreased 55% after 6 months, while mean pain |
| scores decreased 40%. Pain reduction comparing each treatment month to baseline achieved statistical |
| significance. Average pain scores began dropping after only 1 treatment month and continued decreasing each |
| additional month. No organ system experienced adverse effects. Estradiol levels were suppressed during treatment. |
| Side effects were mild and improved over time. Conclusion(s): Fourteen of 15 patients with refractory endometriosis |
| achieved significant pain relief using anastrazole and 20 µg ethinyl estradiol/0.1 mg levonorgestrel with minimal side |
| effects. This treatment for endometriosis is a promising new modality that warrants further investigation. |
| (PubHealth.info Document ID: CONT1T 62-06) |
| PubHealth.info NOTE: The author(s) of this article titled, "Anastrazole and oral contraceptives: a novel treatment for |
| endometriosis.", is(are) Amsterdam LL; Gentry W; Jobanputra S; Wolf M; Rubin SD. The source of this article is |
| "Fertility and Sterility. 2005 Aug;84(2):300-304.". This article was published in 2005 in English language(s). |
| (PubHealth.info® Document ID: CONT1T 62-06. All rights reserved with PubHealth.info) PIN: 62 |
| This article is peer-reviewed. |
|
|
|
© Copyrights PubHealth.info®,
an information portal on public health. All rights
reserved.
This page is optimized to be viewed by
Java script enabled Microsoft®
Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels. |
